Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Double Dose of Tamiflu Offers No Added Benefit in Severe Flu

Published: Tuesday, June 04, 2013
Last Updated: Tuesday, June 04, 2013
Bookmark and Share
Early treatment with Tamiflu is beneficial for patients with uncomplicated flu infection.

Giving double doses of the antiviral drug Tamiflu to patients admitted to hospital with severe flu offers no clinical advantage over the standard dose, according to a randomized trial involving Oxford University researchers based in South East Asia.

This is the first study to look at the effectiveness of higher doses of Tamiflu, or oseltamivir, in cases of severe influenza infection.

The findings have implications for global guidelines on clinical management of severe flu, and also the stockpiling of drugs by national governments for pandemic preparedness, including in the current outbreak of the H7N9 bird flu virus in China.

Professor Jeremy Farrar, head of the Oxford University Clinical Research Unit in Vietnam and director of the South East Asia Infectious Disease Clinical Research Network, led the research. He said: 'The recommendation to give higher doses of oseltamivir to severe cases of flu infection has major implications for clinical management, public health, and planning for antiviral stockpiles but has not been grounded in evidence. Our findings do not support routine use of double doses to treat severe flu infections, which could help to conserve drug stocks in the event of a pandemic.'

The study is published in the medical journal BMJ and was funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Medical Research Council.

Most people who are infected with flu will recover in a few days or up to two weeks. But some people will develop complications, such as difficulty with breathing, that result in hospital admission and can be life-threatening.

Studies have found that early treatment with Tamiflu is beneficial for patients with uncomplicated flu infection and improves survival in hospitalized patients with severe infection. This has led some authorities to recommend double doses of the drug for treatment of patients with severe flu infections.

The new study was conducted by researchers from the South East Asia Infectious Diseases Clinical Research Network, including scientists from Oxford University clinical research units in Indonesia, Thailand and Vietnam.

The trial involved 326 patients with severe flu infection at 13 hospitals in Indonesia, Singapore, Thailand and Vietnam. Most of the patients were children under the age of 15.

Patients were given either a standard dose or double dose of Tamiflu for five days. Their virus levels were monitored for the duration of the treatment along with other outcomes, such as admission to intensive care, the need for mechanical ventilation to assist with breathing and death.

The findings reveal no difference in virus levels at day five between the different doses. There were also no clinical differences in the outcomes for patients, including need for ventilation, time in hospital, deaths, or rates of adverse events.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Tuesday, November 10, 2015
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
Thursday, July 16, 2015
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
Wednesday, January 07, 2015
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Friday, November 07, 2014
New Trial of Personalized Cancer Treatment Begins in Oxford
Phase I trial in Oxford will investigate a new drug, called CXD101.
Tuesday, March 18, 2014
UK Scientists to Begin Trial of Potential HIV Cure
Scientists and clinicians from five leading UK universities will begin a groundbreaking clinical trial next year to test a possible cure for HIV infection.
Tuesday, November 26, 2013
Accelerating Drug Development
Professor Adrian Harris is currently leading a new type of trial to accelerate multi-agent drug development.
Tuesday, March 12, 2013
Oxford's Role in New Meningitis Vaccine
EMA recommends Novartis' Bexero (MenB) vaccine to protect children against meningitis B.
Thursday, November 22, 2012
First Trial of a New Hepatitis C Vaccine Shows Promise
A new vaccine against the chronic liver disease hepatitis C has shown promising results in a first clinical trial in humans, Oxford University researchers report.
Thursday, January 05, 2012
TB Vaccine Enters new Clinical Trials Health
The MVA85A vaccine, developed at the University of Oxford, is to enter Phase IIb proof-of-concept clinical trials.
Thursday, April 23, 2009
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos